Bausch + Lomb Launches Fortifeye Capsular Tension Ring

Source: Bausch + Lomb

Wednesday, July 12, 2017 | Product Releases , Bausch+Lomb


Bausch + Lomb announced the US launch of the FortifEYE capsular tension ring (CTR), a preloaded, sterile, nonoptical implant indicated for the stabilization of the crystalline lens capsule in the presence of weak or partially absent zonules in adult patients undergoing cataract extraction with intraocular lens implantation. Conditions associated with weak or partially absent zonules may include primary zonular weakness (e.g., Marfan syndrome), secondary zonular weakness (e.g., trauma or vitrectomy), cases of zonulysis, cases of pseudoexfoliation, and cases of Weill-Marchesani syndrome.

“Capsular tension rings can play an important role in complex cataract cases, and they must be both effective and easy to use during these procedures,” Chuck Hess, vice president and general manager, U.S. Surgical, Bausch + Lomb, said in a company news release. “The FortifEYE CTR with preloaded single-use injector simplifies insertion allowing for safe, immediate preparation and use.”

The FortifEYE CTRs are sterile, nonoptical implants made up of one continuous piece of polymethyl methacrylate (PMMA), available in both clockwise (right-handed) and counterclockwise (left-handed) insertion options, and are available in a variety of diameters, including 10mm, 11mm, and 12mm (compressed).

CTRs have been shown to preserve the integrity of the capsular bag diameter, capsulorhexis size, and IOL shape, allowing for good anatomical IOL centration. CTRs also have been shown to be a safe and effective ancillary method to delay the incidence, onset, and magnitude of posterior capsular opacification and reduce postsurgical decentration and tilt to allow for excellent optical performance of multifocal and plate-haptic IOLs.


Comments

You must be logged in to leave a comment.